Abstract
The current use of antineoplastic drugs in human therapy causes a substancial number of toxic or side effects which consequently lead to a reduction of the amount of drug to be administered, and in some cases to discontinuation of the therapy. A reduction of the amount of drug to be administered or discontinuation of the therapy causes an increase in primary tumour growth and/or the occurrence of tumour metastases. For this reason, the development of new anti-cancer drugs with lower side effects is necessary. This review gives a general idea about the origins of cancer and the importance of cyclooxygenase-2 (COX-2) in oncogenesis. Evidence from clinical and preclinical studies indicates that COX-2 – derived prostaglandins participate in carcinogenesis, inflammation, immune response suppression, apoptosis inhibition, angiogenesis, and tumour cell invasion and metastasis. The recent anti-tumour drugs are based on tests of known selective COX-2 inhibitors and on the drawing and synthesis of new potent derivatives. Maybe, this can be the way to obtain new anti-tumour drugs with very low collateral effects. Selective COX-2 inhibitors are being mixtured with new anti-cancer drugs in order to obtain better results in the regression of cancers. Some natural products are selective COX-2 inhibitors and have anti-inflammatory and anti-cancer properties. The relevant patents are discussed.
Keywords: Cyclooxygenase, tumour, melatonin, sumatriptan, omega 6, magnesium, indomethacin, selective COX-2 inhibitors
Recent Patents on Anti-Cancer Drug Discovery
Title: Selective Cyclooxygenase-2 (COX-2) Inhibitors Used for Preventing or Regressing Cancer
Volume: 4 Issue: 2
Author(s): Ricardo de Souza Pereira
Affiliation:
Keywords: Cyclooxygenase, tumour, melatonin, sumatriptan, omega 6, magnesium, indomethacin, selective COX-2 inhibitors
Abstract: The current use of antineoplastic drugs in human therapy causes a substancial number of toxic or side effects which consequently lead to a reduction of the amount of drug to be administered, and in some cases to discontinuation of the therapy. A reduction of the amount of drug to be administered or discontinuation of the therapy causes an increase in primary tumour growth and/or the occurrence of tumour metastases. For this reason, the development of new anti-cancer drugs with lower side effects is necessary. This review gives a general idea about the origins of cancer and the importance of cyclooxygenase-2 (COX-2) in oncogenesis. Evidence from clinical and preclinical studies indicates that COX-2 – derived prostaglandins participate in carcinogenesis, inflammation, immune response suppression, apoptosis inhibition, angiogenesis, and tumour cell invasion and metastasis. The recent anti-tumour drugs are based on tests of known selective COX-2 inhibitors and on the drawing and synthesis of new potent derivatives. Maybe, this can be the way to obtain new anti-tumour drugs with very low collateral effects. Selective COX-2 inhibitors are being mixtured with new anti-cancer drugs in order to obtain better results in the regression of cancers. Some natural products are selective COX-2 inhibitors and have anti-inflammatory and anti-cancer properties. The relevant patents are discussed.
Export Options
About this article
Cite this article as:
Pereira de Souza Ricardo, Selective Cyclooxygenase-2 (COX-2) Inhibitors Used for Preventing or Regressing Cancer, Recent Patents on Anti-Cancer Drug Discovery 2009; 4 (2) . https://dx.doi.org/10.2174/157489209788452849
DOI https://dx.doi.org/10.2174/157489209788452849 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Docosahexaenoic Acid (DHA) Sensitizes Brain Tumor Cells to Etoposide-Induced Apoptosis
Current Molecular Medicine Apoptosis-Induction is A Novel Therapeutic Strategy for Gastrointestinal and Liver Cancers
Current Gene Therapy Review of Chemoradiotherapy for High-Risk Prostate Cancer
Reviews on Recent Clinical Trials Applications of the Rare Earth Elements in Cancer Imaging and Therapy
Current Nanoscience Effects of Natural Products on Mcl-1 Expression and Function
Current Medicinal Chemistry Nutrigenomics and Its Approaches for Control of Chronic Diseases
Current Biotechnology Drug Interaction Potential of Trastuzumab Emtansine (T-DM1) Combined with Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer
Current Drug Metabolism NBN Polymorphysms and Cancer Susceptibility: A Systematic Review
Current Genomics Role of CHRNA5-A3 Genetic Locus Variants and Developing Drug for Chronic Obstructive Pulmonary Disease
Current Medicinal Chemistry Liposome Encapsulated All Trans Retinoic Acid (ATRA) has Enhanced Immunomodulatory and Inflammation Reducing Activities in Mice Model
Anti-Cancer Agents in Medicinal Chemistry Resveratrol in Medicinal Chemistry: A Critical Review of its Pharmacokinetics, Drug-Delivery, and Membrane Interactions
Current Medicinal Chemistry Endocrine Therapy for Advanced Breast Cancer: Beyond Tamoxifen and Aromatase Inhibitors
Current Cancer Therapy Reviews Cardiac Side Effects of Chemotherapy: State of Art and Strategies for a Correct Management
Current Vascular Pharmacology Advances in Clinical Study of Curcumin
Current Pharmaceutical Design Recent Studies on Macromolecular Synthesis Labeled with 3H-Thymidine in Various Organs as Revealed by Electron Microscopic Radioautography
Current Radiopharmaceuticals Combination of Phytochemicals as Adjuvants for Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Editorial (Thematic Issue: Revisiting the Revolution: Examining the Evolving Role of Antiangiogenic Therapy in Cancer)
Current Drug Targets MicroRNAs in Cancer: Small Molecules, Big Chances
Anti-Cancer Agents in Medicinal Chemistry Acknowledgements to Reviewers
Current Biomarkers (Discontinued) Pharmacotherapy in Type 2 Diabetes: A Functional Schema for Drug Classification
Current Diabetes Reviews